These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 9072007)
21. Decreased expression of galectin-3 is associated with progression of human breast cancer. Castronovo V; Van Den Brûle FA; Jackers P; Clausse N; Liu FT; Gillet C; Sobel ME J Pathol; 1996 May; 179(1):43-8. PubMed ID: 8691344 [TBL] [Abstract][Full Text] [Related]
22. E-cadherin: a differentiation marker in thyroid malignancies. Brabant G; Hoang-Vu C; Cetin Y; Dralle H; Scheumann G; Mölne J; Hansson G; Jansson S; Ericson LE; Nilsson M Cancer Res; 1993 Oct; 53(20):4987-93. PubMed ID: 8402689 [TBL] [Abstract][Full Text] [Related]
23. CD117 expression in normal, neoplastic, inflammatory, and reactive lesions of the thyroid. Aydin O; Yildiz L; Kefeli M; Kandemir B Pathol Res Pract; 2008; 204(6):359-65. PubMed ID: 18337018 [TBL] [Abstract][Full Text] [Related]
24. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Xu X; Quiros RM; Maxhimer JB; Jiang P; Marcinek R; Ain KB; Platt JL; Shen J; Gattuso P; Prinz RA Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5968-79. PubMed ID: 14676122 [TBL] [Abstract][Full Text] [Related]
25. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570 [TBL] [Abstract][Full Text] [Related]
26. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Weinberger PM; Adam BL; Gourin CG; Moretz WH; Bollag RJ; Wang BY; Liu Z; Lee JR; Terris DJ Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):503-10. PubMed ID: 17515507 [TBL] [Abstract][Full Text] [Related]
27. [Low galectin-3 capacity to discriminate thyroid lesions]. De-León-Mazariegos R; Canedo-Patzi M; Pérez-Enríquez B; Candanedo-Gonzalez F; Saqui-Salces M; Gamboa-Domínguez A; Rull-Rodrigo JA Rev Invest Clin; 2004; 56(5):623-8. PubMed ID: 15776867 [TBL] [Abstract][Full Text] [Related]
29. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634 [TBL] [Abstract][Full Text] [Related]
31. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions. Mataraci EA; Ozgüven BY; Kabukçuoglu F Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608 [TBL] [Abstract][Full Text] [Related]
32. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. Bernet VJ; Anderson J; Vaishnav Y; Solomon B; Adair CF; Saji M; Burman KD; Burch HB; Ringel MD J Clin Endocrinol Metab; 2002 Oct; 87(10):4792-6. PubMed ID: 12364475 [TBL] [Abstract][Full Text] [Related]
33. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma. Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102 [TBL] [Abstract][Full Text] [Related]
34. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. Martins L; Matsuo SE; Ebina KN; Kulcsar MA; Friguglietti CU; Kimura ET J Clin Endocrinol Metab; 2002 Oct; 87(10):4806-10. PubMed ID: 12364477 [TBL] [Abstract][Full Text] [Related]
35. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. Saito T; Endo T; Kawaguchi A; Ikeda M; Katoh R; Kawaoi A; Muramatsu A; Onaya T J Clin Invest; 1998 Apr; 101(7):1296-300. PubMed ID: 9525971 [TBL] [Abstract][Full Text] [Related]
36. Expression of the Mr 67,000 laminin receptor is an adverse prognostic indicator in human thyroid cancer: an immunohistochemical study. Basolo F; Pollina L; Pacini F; Fontanini G; Ménard S; Castronovo V; Bevilacqua G Clin Cancer Res; 1996 Oct; 2(10):1777-80. PubMed ID: 9816129 [TBL] [Abstract][Full Text] [Related]
37. Scanning electron microscopy of the human thyroid gland and its disorders. Nesland JM; Sobrinho-Simoes M; Johannessen JV Scanning Microsc; 1987 Dec; 1(4):1797-810. PubMed ID: 3433063 [TBL] [Abstract][Full Text] [Related]
38. Expression of telomerase genes in thyroid carcinoma. Hoang-Vu C; Boltze C; Gimm O; Poremba C; Dockhorn-Dworniczak B; Köhrle J; Rath FW; Dralle H Int J Oncol; 2002 Aug; 21(2):265-72. PubMed ID: 12118320 [TBL] [Abstract][Full Text] [Related]
39. Heterogeneous distribution of thyrotrophin receptor messenger ribonucleic acid (TSH-R mRNA) in papillary thyroid carcinomas detected by in situ hybridization. Tanaka K; Inoue H; Miki H; Komaki K; Monden Y Clin Endocrinol (Oxf); 1996 Mar; 44(3):259-67. PubMed ID: 8729520 [TBL] [Abstract][Full Text] [Related]
40. CA 50 and CA 19-9 antigen expression in normal, hyperplastic, and neoplastic thyroid tissue. Vierbuchen M; Schröder S; Uhlenbruck G; Ortmann M; Fischer R Lab Invest; 1989 May; 60(5):726-32. PubMed ID: 2716285 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]